keyword
MENU ▼
Read by QxMD icon Read
search

PMBCL

keyword
https://www.readbyqxmd.com/read/28634685/poor-predictive-value-of-positive-interim-fdg-pet-ct-in-primary-mediastinal-large-b-cell-lymphoma
#1
Julien Lazarovici, Marie Terroir, Julia Arfi-Rouche, Jean-Marie Michot, Sacha Mussot, Valentina Florea, Maria-Rosa Ghigna, Peggy Dartigues, Cynthia Petrovanu, Alina Danu, Christophe Fermé, Vincent Ribrag, David Ghez
PURPOSE: Though commonly used to assess response to therapy, the prognostic value of interim FDG-PET/CT in Primary Mediastinal Large B-cell Lymphoma (PMBCL) is unclear. METHODS: We conducted a retrospective study on 36 consecutive patients treated at our institution for a PMBCL between 2006 and 2014. All patients with a positive interim FDG-PET/CT had undergone histological restaging consisting either in a surgical debulking of the residual lesion (15 patients) or a CT-guided core needle biopsy (two patients)...
June 21, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28532396/addition-of-rituximab-to-chop-like-chemotherapy-in-first-line-treatment-of-primary-mediastinal-b-cell-lymphoma
#2
K Lisenko, G Dingeldein, M Cremer, M Kriegsmann, A D Ho, M Rieger, M Witzens-Harig
BACKGROUND: The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) -like therapy has improved survival in primary mediastinal B-cell lymphoma (PMBCL) patients. However, these results were obtained in young low risk patients and a reevaluation in an unselected patient cohort is warranted. METHODS: In this study, we analyzed 80 PMBCL patients treated with a CHOP-based regimen with and without rituximab. RESULTS: In the non-rituximab cohort 10-year progression free survival (PFS) was 67% and 10-year overall survival (OS) was 72% versus a PFS of 95% and a OS of 92% in the rituximab group, PFS P = 0...
May 22, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28490569/safety-tolerability-of-pembrolizumab-in-patients-with-relapsed-refractory-primary-mediastinal-large-b-cell-lymphoma
#3
Pier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, Jean-Marie Michot, John Kuruvilla, Arun Balakumaran, Yayan Zhang, Sabine Chlosta, Margaret A Shipp, Philippe Armand
Treatment options for relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) are limited and prognosis is generally poor (overall response rate [ORR] 0-25%; 2-year overall survival 15%). PMBCL frequently involves PD-1 ligand overexpression, potentially making PMBCL particularly susceptible to PD-1 blockade. We evaluated safety and antitumor activity of pembrolizumab, an anti-PD-1 antibody, in rrPMBCL as part of the KEYNOTE-013 multicohort Phase 1b trial. At time of data cutoff, 18 patients (median age 30; median 3 prior lines of therapy) had been enrolled and treated, of whom 17 were included in the efficacy analyses...
May 10, 2017: Blood
https://www.readbyqxmd.com/read/28179969/composite-lymphoma-opposite-ends-of-spectrum-meet
#4
Uqba Khan, Tarik Hadid, Warda Ibrar, Dahlia Sano, Ayad Al-Katib
An 18-year-old African-American female presented with an episode of syncope. Initial investigations revealed large lung mass with invasion into right atrium along with lesions in kidneys and liver. Patient also developed superior vena cava syndrome due to lung mass. Biopsy of lung mass revealed diagnosis of composite lymphoma with involvement by primary mediastinal B-cell lymphoma (PMBCL) and classical Hodgkin lymphoma. Patient was started on dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) with complete response to treatment...
March 2017: Journal of Clinical Medicine Research
https://www.readbyqxmd.com/read/28144055/primary-mediastinal-lymphomas-their-morphological-features-and-comparative-evaluation
#5
Riti Aggarwal, Seema Rao, Shashi Dhawan, Sunita Bhalla, Arvind Kumar, Prem Chopra
BACKGROUND: Primary mediastinal lymphoma is an uncommon tumor. Hodgkin's lymphoma (HL), primary mediastinal B-cell lymphoma (PMBCL), and T-lymphoblastic lymphoma are the most common primary mediastinal lymphomas. Key morphological and immunohistochemistry (IHC) features play a very crucial role in diagnosis as well as further categorization. MATERIALS AND METHODS: In this study, the morphological spectrum and histological features of 32 cases of primary mediastinal lymphomas diagnosed over 5 years were studied and morphological and IHC features of PMBCL versus HL were compared...
January 2017: Lung India: Official Organ of Indian Chest Society
https://www.readbyqxmd.com/read/28078727/second-cancer-incidence-in-primary-mediastinal-b-cell-lymphoma-treated-with-methotrexate-with-leucovorin-rescue-doxorubicin-cyclophosphamide-vincristine-prednisone-and-bleomycin-regimen-with-or-without-rituximab-and-mediastinal-radiotherapy-results-from-a-monoinstitutional
#6
Vitaliana De Sanctis, Marco Alfò, Alice Di Rocco, Michela Ansuinelli, Eleonora Russo, Mattia F Osti, Maurizio Valeriani, Giuseppe Minniti, Lavinia Grapulin, Daniela Musio, Stefano Bracci, Alessandra Spagnoli, Maria Luisa Moleti, Vincenzo Tombolini, Maurizio Martelli
Our aim is to assess the incidence of second cancer in long-time surviving primary mediastinal B-cell lymphoma (PMBCL) patients treated with combined radiochemoimmunotherapy (standard methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin with rituximab and mediastinal radiation therapy at a dose of 30 to 36 Gy). For this purpose, 92 points were evaluated. After a median overall survival of 137 months (range 76-212), we recorded second cancer in 3 of 80 long-surviving patients (3...
January 12, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/27688726/primary-mediastinal-b-cell-lymphoma-metabolic-and-anatomical-features-in-18fdg-pet-ct-and-response-to-therapy
#7
Anna Kocurek, Bogdan Małkowski, Agnieszka Giza, Wojciech Jurczak
AIM OF THE STUDY: Determining the role of PET/CT imaging in the evaluation of treatment efficacy in primary mediastinal B-cell lymphoma (PMBCL). MATERIAL AND METHODS: Retrospective analysis of seven PMBCL patients, treated at the University Hospital in Krakow, with interim PET/CT after the third course of chemo-immunotherapy.The analysis was based on the calculation of exact tumour volume and metabolic activity, compared with initial values (directly after diagnosis)...
2016: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/27675775/utilization-of-positron-emission-tomography-computed-tomography-parameters-to-identify-patients-at-risk-for-progression-after-treatment-with-dose-adjusted-r-epoch-for-primary-mediastinal-b-cell-lymphoma-pmbcl
#8
C C Pinnix, Z Abou Yehia, W Qiao, S A Milgrom, G L Smith, M Akhtari, J Reddy, J R Gunther, E M Osborne, O R Mawlawi, L J Medeiros, N Garg, H H Chuang, S Neelapu, J R Westin, B Dabaja
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27623181/mediastinal-gray-zone-lymphoma-with-features-intermediate-between-classical-hodgkin-lymphoma-and-primary-mediastinal-b-cell-lymphoma
#9
COMMENT
Haa-Na Song, Seok Jin Kim, Young Hyeh Ko, Won Seog Kim
BACKGROUND: Mediastinal gray zone lymphoma (MGZL) shares clinical characteristics with primary mediastinal B-cell lymphoma (PMBCL) and nodular sclerosing Hodgkin lymphoma (NSHL). However, MGZL is extremely rare, and an appropriate treatment for it has not yet been established. METHODS: We retrospectively analyzed 8 patients who were treated with systemic chemotherapy for MGZL between 2007 and 2014. RESULTS: The patients with MGZL were predominantly young and male (median age 26 years), and 62...
2016: Acta Haematologica
https://www.readbyqxmd.com/read/27545416/training-improves-the-interobserver-agreement-of-the-expert-positron-emission-tomography-review-panel-in-primary-mediastinal-b-cell-lymphoma-interim-analysis-in-the-ongoing-international-extranodal-lymphoma-study-group-37-study
#10
Luca Ceriani, Sally Barrington, Alberto Biggi, Bogdan Malkowski, Ur Metser, Annibale Versari, Maurizio Martelli, Andrew Davies, Peter W Johnson, Emanuele Zucca, Stéphane Chauvie
The International Extranodal Lymphoma Study Group (IELSG)-37 is a prospective randomized trial assessing the role of consolidation mediastinal radiotherapy after immunochemotherapy to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMBCL). It is a positron emission tomography (PET) response-guided study where patients obtaining a complete metabolic response on an end-of-therapy PET-computed tomography (CT) scan evaluated by a central review are randomized to receive radiotherapy or no further treatment...
August 22, 2016: Hematological Oncology
https://www.readbyqxmd.com/read/27459613/-therapy-for-primary-mediastinal-large-b-cell-lymphoma-in-accordance-with-the-r-da-epoch-21-program-the-first-results
#11
Ya K Mangasarova, A U Magomedova, E S Nesterova, E M Volodicheva, V I Vorobyev, S K Kravchenko
AIM: to evaluate the efficiency of the R-DA-EPOCH-21 + R-DHAP protocol and autologous hematopoietic stem cell transplantation (a BEAM conditioning mode) in first-line therapy for primary mediastinal large B-cell lymphoma (PMBCL). SUBJECTS AND METHODS: In 2013 to 2016, the investigation enrolled 57 patients with newly diagnosed PMBCL (according to the 2008 WHO criteria). The results were analyzed in 40 patients who had completed their treatment. RESULTS: All the 40 patients (14 men and 26 women) (median age, 27 years (19 to 67 years)) received 6 cycles of polychemotherapy (PCT) in accordance with the R-DA-EPOCH-21 regimen...
2016: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/27417993/bowel-perforation-from-occult-ileal-involvement-after-diagnosis-in-a-case-of-primary-mediastinal-large-b-cell-lymphoma
#12
Chiara De Philippis, Maria Chiara Di Chio, Elena Sabattini, Niccolo Bolli
Primary mediastinal large B-cell lymphoma (PMBCL) is confined to the mediastinum or contiguous nodal areas in most cases. Extramediastinal and abdominal involvement, especially at diagnosis, is extremely rare. Our case describes the first case of histologically proven ileal involvement of PMBCL at diagnosis that led to ileal perforation. Positron emission tomography CT could increase the sensitivity of staging by detecting unusual sites of disease localisation, and could impact clinical management.
July 14, 2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27130796/prognostic-role-of-pre-radiation-therapy-18-f-fluorodeoxyglucose-positron-emission-tomography-for-primary-mediastinal-b-cell-lymphomas-treated-with-r-chop-or-r-chop-like-chemotherapy-plus-radiation
#13
Andrea Riccardo Filippi, Cristina Piva, Mario Levis, Annalisa Chiappella, Daniele Caracciolo, Marilena Bellò, Gianni Bisi, Umberto Vitolo, Umberto Ricardi
PURPOSE: To validate, in a monoinstitutional cohort with extended follow-up, that post-rituximab chemotherapy (R-CT) (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) is a prognostic factor allowing discrimination of primary mediastinal B-cell lymphoma (PMBCL) patients at higher risk for progression after radiation therapy. METHODS AND MATERIALS: We analyzed 51 patients, and (18)FDG-PET scans were re-examined evaluating both the Deauville 5-point scale (D5PS) score and the standardized uptake value (SUV) of residual activity, if present...
July 15, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/26957476/mediastinal-gray-zone-lymphoma-a-wider-category-than-we-think
#14
Anuj Verma, Tanuja Shet, Sridhar Epari, Manjudevi Gupta, Sumeet Gujral, Nehal Khanna, Siddhartha Laskar, Manju Sengar, Brijesh Arora, Hari Menon, Shripad Banavali
AIM: To identify aggressively behaving classical Hodgkin lymphoma (CHL) of mediastinum and primary mediastinal B-cell lymphoma (PMBCL) and to classify them as mediastinal gray zone lymphoma(MGZL) and to define a minimum immunopanel for the diagnosis of MGZL. MATERIALS AND METHODS: Ninety-two mediastinal B-cell lymphomas were reviewed with a wide immunopanel and were classified as CHL, PMBCL, or MGZL. CHL with an expression of 3 or 4 transcription factors performed worse, and hence the CHL with ≥3 transcription factors were classified as MGZL-CHL...
August 2016: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/26852276/improved-survival-with-combined-modality-therapy-in-the-modern-era-for-primary-mediastinal-b-cell-lymphoma
#15
Matthew W Jackson, Chad G Rusthoven, Bernard L Jones, Manali Kamdar, Rachel Rabinovitch
Primary mediastinal B-cell lymphoma (PMBCL) is an uncommon lymphoma for which existing data is limited. We utilized the National Cancer Database (NCDB) to evaluate PMBCL and the impact of radiotherapy (RT) on outcomes in the years following FDA approval of rituximab. We queried the NCDB for patients with PMBCL diagnosed from 2006 to 2011 and treated with multiagent chemotherapy. Kaplan-Meier overall survival (OS) estimates, univariate (UVA), and multivariate (MVA) Cox proportional hazards regression analyses were performed...
May 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/26549456/genomic-alterations-in-ciita-are-frequent-in-primary-mediastinal-large-b-cell-lymphoma-and-are-associated-with-diminished-mhc-class-ii-expression
#16
Anja Mottok, Bruce Woolcock, Fong Chun Chan, King Mong Tong, Lauren Chong, Pedro Farinha, Adèle Telenius, Elizabeth Chavez, Suvan Ramchandani, Marie Drake, Merrill Boyle, Susana Ben-Neriah, David W Scott, Lisa M Rimsza, Reiner Siebert, Randy D Gascoyne, Christian Steidl
Primary mediastinal large B cell lymphoma (PMBCL) is an aggressive non-Hodgkin's lymphoma, predominantly affecting young patients. We analyzed 45 primary PMBCL tumor biopsies and 3 PMBCL-derived cell lines for the presence of genetic alterations involving the major histocompatibility complex (MHC) class II transactivator CIITA and found frequent aberrations consisting of structural genomic rearrangements, missense, nonsense, and frame-shift mutations (53% of primary tumor biopsies and all cell lines). We also detected intron 1 mutations in 47% of the cases, and detailed sequence analysis strongly suggests AID-mediated aberrant somatic hypermutation as the mutational mechanism...
November 17, 2015: Cell Reports
https://www.readbyqxmd.com/read/26547384/improved-survival-with-radiation-therapy-in-stage-i-ii-primary-mediastinal-b-cell-lymphoma-a-surveillance-epidemiology-and-end-results-database-analysis
#17
Matthew W Jackson, Chad G Rusthoven, Bernard L Jones, Manali Kamdar, Rachel Rabinovitch
BACKGROUND: Primary mediastinal B cell lymphoma (PMBCL) is an uncommon lymphoma for which trials are few with small patient numbers. The role of radiation therapy (RT) after standard immunochemotherapy for early-stage disease has never been studied prospectively. We used the Surveillance, Epidemiology, and End Results (SEER) database to evaluate PMBCL and the impact of RT on outcomes. METHODS AND MATERIALS: We queried the SEER database for patients with stage I-II PMBCL diagnosed from 2001 to 2011...
January 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/26294712/quantitative-fdg-pet-a-new-biomarker-in-pmbcl
#18
COMMENT
Michel Meignan
In this issue of Blood, Ceriani et al introduce, in primary mediastinal B-cell lymphoma (PMBCL), a new prognostic factor measured on pretreatment 18F-fluorodeoxyglucose (18FDG)-positron emission tomography (PET)/computed tomography (CT): the total lesion glycolysis (TLG), which is an index of the glucose uptake by the total tumor burden. This paper is part of the International Extranodal Lymphoma Study Group (IELSG) 26 prospective study designed to evaluate the role of PET in the treatment of PMBCL.
August 20, 2015: Blood
https://www.readbyqxmd.com/read/26270899/role-of-radiation-therapy-in-primary-mediastinal-large-b-cell-lymphoma-in-rituximab-era-a-us-population-based-analysis
#19
Smith Giri, Vijaya Raj Bhatt, Ranjan Pathak, R Gregory Bociek, Julie M Vose, James O Armitage
The use of radiation (RT) in primary mediastinal large B-cell lymphoma (PMBCL) may predispose young patients to the risk of cardiopulmonary toxicities and secondary malignancies. We used Surveillance, Epidemiology and End Results (SEER) 18 database to compare the overall survival (OS) differences among adult patients treated with and without RT after rituximab approval in the US. Multivariate analyses were performed using Cox proportional hazards regression to compare OS based on the use of RT while adjusting for age, year of diagnosis, race, stage and gender...
November 2015: American Journal of Hematology
https://www.readbyqxmd.com/read/26261675/clear-cell-variant-of-diffuse-large-b-cell-lymphoma-a-case-report-and-review-of-the-literature
#20
Yongjie Xue, Qiulan Wang, Xuejiao He
Diffuse large B cell lymphoma (DLBCL) is a diffuse proliferation of large neoplastic B lymphoid cells with nuclear size equal to or exceeding that of normal macrophage nuclei. The DLBCL morphological variants are centroblastic, immunoblastic, T-cell- and histiocyte-rich, anaplastic, plasmablastic, anaplastic lymphoma kinase-positive, and primary mediastinal large B-cell lymphoma (PMBCL). These histopathologically-recognized morphological variants respond differently to treatment and have distinct prognoses...
2015: International Journal of Clinical and Experimental Pathology
keyword
keyword
100313
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"